🇬🇧·4h agoRegulatory
Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27
Publisher
M
MHRA UK
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gov.uk
Leave the platform to read the original full article on the publisher site.
Source: MHRA UK
Scope: Regulatory
Related coverage
More related coverage
ABPI UK·3h ago
Taking control: Inspiring others to beat rare diseases
ABPI UK·4h ago
Medicine levy makes the UK un-investable, say pharma leaders
LEEM France·7h ago
Le Leem dévoile son Plan Compétences Biotech 2030 à l’occasion de la JNBB 2026
AEMPS (Spain)·7h ago